Randomized phase 2 trial of nab-paclitaxel plus gemcitabine, 6 capecitabine, cisplatin ( paxg regimen) in metastatic pancreatic adenocarcinoma

被引：0
|
作者：
Zanon, S. [1 ]
Pircher, C. [1 ]
Chiaravalle, M. [1 ]
Macchini, M. [1 ]
Peretti, U. [1 ]
Balzano, G. [1 ]
Passoni, P. [1 ]
Nicoletti, R. [1 ]
Arcidiacono, P. G. [1 ]
Pepe, G. [1 ]
Doglioni, C. [1 ]
Romi, S. [1 ]
Gritti, E. [1 ]
Falconi, M. [1 ]
Gianni, L. [1 ]
Reni, M. [1 ]
机构：
[1] IRCCS San Raffaele Sci Inst, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
D3
引用
收藏
页码：44 / 45
页数：2
相关论文
共 50 条
  • [21] nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial
    Mustapha Tehfe
    Scot Dowden
    Hagen Kennecke
    Robert El-Maraghi
    Bernard Lesperance
    Felix Couture
    Richard Letourneau
    Helen Liu
    Alfredo Romano
    Advances in Therapy, 2016, 33 : 747 - 759
  • [22] nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial
    Tehfe, Mustapha
    Dowden, Scot
    Kennecke, Hagen
    El-Maraghi, Robert
    Lesperance, Bernard
    Couture, Felix
    Letourneau, Richard
    Liu, Helen
    Romano, Alfredo
    ADVANCES IN THERAPY, 2016, 33 (05) : 747 - 759
  • [23] A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer
    Bodeker, Kellie L.
    Smith, Brian J.
    Berg, Daniel J.
    Chandrasekharan, Chandrikha
    Sharif, Saima
    Fei, Naomi
    Vollstedt, Sandy
    Brown, Heather
    Chandler, Meghan
    Lorack, Amanda
    McMichael, Stacy
    Wulfekuhle, Jared
    Wagner, Brett A.
    Buettner, Garry R.
    Allen, Bryan G.
    Caster, Joseph M.
    Dion, Barbara
    Kamgar, Mandana
    Buatti, John M.
    Cullen, Joseph M.
    REDOX BIOLOGY, 2024, 77
  • [24] The nab-paclitaxel/gemcitabine regimen for patients with refractory advanced pancreatic adenocarcinoma
    Palacio, Sofia
    Hosein, Peter J.
    Reis, Isildinha
    Akunyili, Ikechukwu I.
    Ernani, Vinicius
    Pollack, Terri
    Macintyre, Jessica
    Restrepo, Maria H.
    Merchan, Jaime R.
    Lima, Caio M. Rocha
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2018, 9 (01) : 135 - 139
  • [25] Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial
    Bekaii-Saab, Tanios
    Okusaka, Takuji
    Goldstein, David
    Oh, Do-Youn
    Ueno, Makoto
    Ioka, Tatsuya
    Fang, Weijia
    Anderson, Eric C.
    Noel, Marcus S.
    Reni, Michele
    Choi, Hye Jin
    Goldberg, Jonathan S.
    Oh, Sang Cheul
    Li, Chung-Pin
    Tabernero, Josep
    Li, Jian
    Foos, Emma
    Oh, Cindy
    Van Cutsem, Eric
    ECLINICALMEDICINE, 2023, 58
  • [26] Erratum to: nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial
    Mustapha Tehfe
    Scot Dowden
    Hagen Kennecke
    Robert El-Maraghi
    Bernard Lesperance
    Felix Couture
    Richard Letourneau
    Helen Liu
    Alfredo Romano
    Advances in Therapy, 2017, 34 : 277 - 279
  • [27] Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
    Weiss, Glen J.
    Blaydorn, Lisa
    Beck, Julia
    Bornemann-Kolatzki, Kirsten
    Urnovitz, Howard
    Schutz, Ekkhard
    Khemka, Vivek
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (01) : 96 - 102
  • [28] Gabrinox: A phase I-II of nab-paclitaxel plus gemcitabine followed by folfirinox in metastatic pancreatic adenocarcinoma
    Assenat, E.
    de la Fouchardiere, C.
    Mollevi, C.
    Samalin, E.
    Portales, F.
    Desseigne, F.
    Carenco, C.
    Dupuy, M.
    Lopez-Martinez, E.
    Fiess, C.
    Mazard, T.
    Ychou, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [29] Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
    Glen J. Weiss
    Lisa Blaydorn
    Julia Beck
    Kirsten Bornemann-Kolatzki
    Howard Urnovitz
    Ekkhard Schütz
    Vivek Khemka
    Investigational New Drugs, 2018, 36 : 96 - 102
  • [30] Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
    Von Hoff, Daniel D.
    Ramanathan, Ramesh K.
    Borad, Mitesh J.
    Laheru, Daniel A.
    Smith, Lon S.
    Wood, Tina E.
    Korn, Ronald L.
    Desai, Neil
    Trieu, Vuong
    Iglesias, Jose L.
    Zhang, Hui
    Soon-Shiong, Patrick
    Shi, Tao
    Rajeshkumar, N. V.
    Maitra, Anirban
    Hidalgo, Manuel
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (34) : 4548 - 4554
12345